These criteria assess metabolic status, cardiovascular risk, and treatment goals to determine if GLP-1 aligns with a patient's health profile and whether it offers benefit beyond current management strategies
Dondero K, et al
No TUNEL positive cells are found in the control or in the GSH-treated (5mM) cells in cultures
17 Rosenstock, J., et al., Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
van Opbergen CJM, Bagwan N, Maurya SR, Kim JC, Smith AN, Blackwell DJ, Johnston JN, Knollmann BC, Cerrone M, Lundby A, Delmar M
VK2735 sheds weight twice as fast as Zepbound and 5x faster than Wegovy